WAYNE, Pa., Sept. 19, 2016 /PRNewswire/ -- Egalet
Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty
pharmaceutical company focused on developing, manufacturing and
commercializing innovative treatments for pain and other conditions
today announced the appointment of Patrick
Shea as chief commercial officer (CCO). Mr. Shea will be
responsible for leading Egalet's commercial activities and will
report to Bob Radie, Egalet's chief
executive officer.
In his role Mr. Shea will be responsible for developing and
implementing the commercialization strategy for OXAYDO®
(oxycodone HCI, USP) tablets for oral use only –CII,
SPRIX® (ketorolac tromethamine) Nasal Spray, ARYMO™ ER
(morphine sulfate) extended-release tablets which is under review
at the U.S. Food and Drug Administration and additional Guardian™
Technology pipeline products as they are developed.
"With his extensive pharmaceutical and biotechnology sales and
marketing experience, including his intimate knowledge of payor
dynamics and product launch leadership, Pat will be an extremely
valuable asset to Egalet as we prepare to launch ARYMO ER, pending
FDA approval, in the first quarter of 2017," said Mr. Radie.
Mr. Shea has over two decades of sales, marketing, market access
and commercial operations experience. Most recently Mr. Shea served
as CCO at Clarus Therapeutics, Inc., a men's health specialty
pharmaceutical company. Prior to Clarus he served as vice president
of sales and marketing for the U.S. commercial operations of CSL
Behring, where he oversaw strategic efforts for sales, marketing
and managed care business. Before that he served as senior vice
president of sales and marketing for the U.S. pharmaceutical
operations at Astellas Pharmaceuticals, and held senior sales and
marketing roles at Ligand Pharmaceuticals and Boehringer Ingelheim.
Mr. Shea received his bachelor's degree in Psychology from
Alfred University.
About Egalet
Egalet, a fully integrated specialty
pharmaceutical company, is focused on developing, manufacturing and
commercializing innovative treatments for pain and other
conditions. Egalet has two approved products: OXAYDO®
(oxycodone HCI, USP) tablets for oral use only –CII and
SPRIX® (ketorolac tromethamine) Nasal Spray. In
addition, using its proprietary Guardian™ Technology, Egalet is
developing a pipeline of clinical-stage, product candidates that
are specifically designed to deter abuse by physical and chemical
manipulation. The lead programs, ARYMO™ ER, an
abuse-deterrent, extended-release, oral morphine formulation, and
Egalet-002, an abuse-deterrent, extended-release, oral oxycodone
formulation, are being developed for the management of pain severe
enough to require daily, around-the-clock, long-term opioid
treatment and for which alternative treatment options are
inadequate. Egalet's Guardian Technology can be applied broadly
across different classes of pharmaceutical products and can be used
to develop combination products that include multiple active
pharmaceutical ingredients with similar or different release
profiles. For additional information on Egalet, please visit
egalet.com. For full prescribing information on SPRIX, including
the boxed warning, please visit sprix.com. For full prescribing
information on OXAYDO, please visit oxaydo.com.
Safe Harbor
Statements included in this press release
(including but not limited to anticipated labeling for ARYMO ER)
that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are based on management's
current expectations, and are subject to known and unknown
uncertainties and risks. Actual results could differ materially
from those discussed due to a number of factors, including, but not
limited to: the success of Egalet's clinical trials, including the
timely recruitment of trial subjects and meeting the timelines
therefor; Egalet's ability to obtain regulatory approval of its
product candidates; Egalet's ability to maintain the intellectual
property position of its products and product candidates; Egalet's
ability to identify and reliance upon qualified third parties to
manufacture its products; Egalet's ability to service its debt
obligations; Egalet's ability to raise additional funds related to
execute its business plan and growth strategy in terms acceptable
to Egalet, if at all; Egalet's ability to find and hire qualified
sales professionals; the receptivity in the marketplace and among
physicians to Egalet's products; the success of products which
compete with Egalet's that are or become available; general market
conditions; and other risk factors described in Egalet's filings
with the United States Securities and Exchange Commission. Egalet
assumes no obligation to update or revise any
forward-looking-statements contained in this press release whether
as a result of new information or future events, except as may be
required by law.
Investor and Media Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: bcs@egalet.com
Tel: 917-432-9275
Logo -
http://photos.prnewswire.com/prnh/20140219/NY67493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/egalet-appoints-patrick-shea-as-chief-commercial-officer-300329875.html
SOURCE Egalet Corporation